Pharmaceutical Technology

JUNE 24, 2022

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.

Biopharma 64

Biopharma Pharma Pharmacology Healthcare 64

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.

Pharma 101

Pharma Food and Drug Administration Recruitment Pharmacology 101

pharmaphorum

DECEMBER 20, 2022

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. Although, so far efforts to bring a therapy to market have failed.

Pharmacology 52

Pharmacology Pharma Marketing Biopharma 52

Pharmaceutical Technology

MAY 24, 2023

Several tetrapeptides are pharmacologically active, showing affinity and specificity for multiple receptors in protein-protein signalling. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Merck 42 Unlock company profile C.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

Clarivate

FEBRUARY 28, 2023

LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.

Prescription 98

Prescription Patients Pharmacology Healthcare 98